Liraglutide
Saxenda, Victoza
GLP-1 Receptor Agonist
NADAC/unit
$39.4317
Active Shortage
Tier 1: 7.9%
PA Req: 29.5%
6 Manufacturers
8 ANDAs
Liraglutide lowers blood sugar and promotes weight loss by mimicking the GLP-1 hormone, used in type 2 diabetes.
vs. brand Saxenda: Generic saves up to -294% per unit
Active Shortages
2023-07-18 Product will be made available as it is released., Hikma Pharmaceuticals USA, Inc.
2023-07-18 Shortage reported, Novo Nordisk, Inc.
2023-07-18 Shortage reported, Meitheal Pharmaceuticals, Inc.
2023-07-18 Distributed by Teva, Novo Nordisk, Inc.
2023-07-18 Estimated shortage duration TBD, Novo Nordisk, Inc.
Generic Manufacturers
BIOCON PHARMA LTDHIKMA PHARMACEUTICALS USA INCLUPIN LTDNANJING KING FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTDNOVO NORDISK INCORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTDTEVA PHARMACEUTICALS DEVELOPMENT INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.